CVS raised its 2026 adjusted EPS forecast to $7.90-$8.10, exceeding analyst estimates of $7.45 after Q2 results.
CVS Health increased its 2026 adjusted earnings per share forecast to a range of $7.90 to $8.10, up from prior guidance of $7.30 to $7.50. The revision follows a second-quarter profit of $2.58 per share, surpassing analysts’ expectations of $1.85.
The company attributed the improved outlook to a more profitable mix of drugs in its pharmacy business and higher payments for its government health plans. Aetna, CVS’s insurance unit, reported a medical loss ratio of 87.4%, down from 89.9% a year earlier and below estimates of 90.03%.
CVS also announced $29 appointments for weight-loss drug consultations at its MinuteClinic, including treatments like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The results mark the sixth consecutive quarterly beat for the company.